In the meantime, US researchers are reporting good news.
They claim that they can resist coronavirus; they have successfully tested in the laboratory with drugs or pills that they take in the mouth.
A group of researchers from the University of Emory, the University of North Carolina, and Vanderbilt University Medical Center researched the new drug. Meanwhile, a US company called Ridgeback Biotherapeutics has obtained a license for the drug. The US Food and Drug Administration (FDA) has also approved drug testing.
In the next few months, five patients will be tested with virus-resistant drugs.
Miami-based Ridgeback Biotherapeutics in Florida is a privately-owned biotechnology organization dealing with infectious diseases.
Researchers at the Emory Institute for Drug Development say the drug is 'EIDD-20'. It mainly blocks the reproduction and transmission of high numbers of SARS-Cove-2 viruses. Research articles have been published in the journal 'Science Translational Medicine.' The pill has been shown to prevent the transmission of coronavirus to human lung cell transcripts in test tubes. Also, they have studied this drug on rats. In this case, they have been shown to prevent the regeneration of the coronavirus, which is closely related to the rat and to improve lung function.
Researchers say their drug has not yet been tested in humans. But if the effect is similar to that of humans, this will be the first pill to cause a Covid-I pandemic.
According to Johns Hopkins University in the United States, the number of patients with coronavirus has increased by 1 million 20 thousand 5 by Wednesday morning. Worldwide, coronavirus has died of 12 thousand 5 people. Of those, 1,827 died in Italy, the highest in any country so far.
Experts say that it would be a blessing if you get coronary medicine as an oral pill or pill because it would be easier for more people to give drugs than to get injected into the veins.
Earlier, a joint team of researchers from universities found that Gilead Science's experimental remodecavage drug was effective in stopping the transcription of coronaviruses. An antiviral drug from an American biotechnology company called Gilead Science is now used in small numbers for some patients. Its name is Remedecavir, and in science, it is called the nucleotide analog. It is a compound similar to the original mixture that DNA is made of. Some of these drugs are currently used to prevent HIV. Remediation was developed to avoid the Ebola virus in Africa. It is a broad-spectrum virus resistant. That means it works to prevent several infections, such as Nipa, MARS, SARS, Ebola, and some other illnesses. In January this year, the drug was applied to a Washington state patient.
Remedies are currently under discussion because experts have begun clinical trials against the SARS-Cove-2 virus last March. The end can know the results of April.
Researchers claim that EIDD-20 will prevent the transcription of coronavirus successfully compared to Gilead's drugs.
George Painter, executive director of the Emory Institute for Drug Development and professor of chemistry, said the findings of the study are essential considering the current Covid-1 problem.
At 28, Painter and his lab researchers discovered the activities of EIDD-20 while searching for influenza drugs. Before the Corona pandemic last October, Emory National Institute of Allergy and Infectious Disease received $ 1 million in funding. Emory University got the money to test the people against the flu virus. However, when the coronavirus hit, the Painter's research team changed their focus.
EIDD-20 prevents coronavirus's self-copy activity in a way that is different from remodecavirus. The original copywriting process completely stopped. EIDD-20 damages mutations in the virus's RNA, so that RNA is damaged and cannot damage cells. It is also capable of acting against other RNA viruses. So it will be useful as a multiple anti-virus drug. Some antibiotics, such as EIDD-20, can work for various bacteria.
Wayne Holman, the co-founder of Ridgeback Biotherapeutics, a US-based Miami-based company, said the compound they created could be beneficial for health workers, primarily to prevent prophylaxis or infection. Another possible use is to protect the residents and staff of the nursing home from outbreaks. The broader goal, however, is to make mouth pills, which can be given to the patient twice a day at the beginning of the disease.
Ridgeback Biotherapeutics has applied for a test in the United Kingdom in addition to starting a US test. "We worked three to four years in three to four weeks to prevent the new Corona epidemic," Holman said. References: Essence News, Scientific American
You must be logged in to post a comment.